Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-blind, Active-controlled Multi-center Study to Evaluate the Efficacy, Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia

NCT06355479 is registered in ClinicalTrials.gov with Healthgen Biotechnology Corp. as lead sponsor.

NCT NCT06355479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06355479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-blind, Active-controlled Multi-center Study to Evaluate the Efficacy, Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia
Lead sponsor
Healthgen Biotechnology Corp.
Phase
Phase 3
Overall status
Completed
Start date
April 10, 2023
Completion date
December 12, 2023
Enrollment
328 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic cirrhosis, hypoalbuminemia